ArticleAmerican journal of translational research2026
Predictive value of systemic inflammatory response index for the occurrence and prognosis of lung metastases in papillary thyroid carcinoma.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the predictive value of the systemic immune-inflammation index (SIRI) for the timing and prognosis of lung metastases in patients with papillary thyroid carcinoma (PTC) post-surgery and before the first
methodsThis retrospective study collected clinical data from 234 outpatients who underwent total or subtotal thyroidectomy followed by their first
resultsStatistically significant differences were found between the groups in terms of SIRI, pre-ablation thyroglobulin (Ps-Tg), maximum tumor diameter, and whether the tumor was multifocal (all P<0.05). Patients with higher SIRI values, higher Ps-Tg levels, larger main tumors, and more multiple tumors were more likely to develop lung metastases (all P<0.05). SIRI was effective in diagnosing lung metastases in patients with PTC, with an area under the curve (AUC) of 0.834 and an optimal cutoff value of 0.64. Overall, in all cases, the disease control rate and progression-free survival were significantly higher in the low-SIRI group than in the high-SIRI group (both P<0.05).
conclusionSIRI prior to the first
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.